#cancer
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Jul 2023 – Apr 2024Where it's discussed
-
X / Twitter21 posts
-
Facebook2 posts
-
News2 articles
-
YouTube1 videos
AI synopsis
What people are saying
The discussions reflect a positive stance towards the article, with phrases like 'exciting frontier' and 'potential to aid in diagnosis' illustrating enthusiasm for the technology's promise. The tone and word choice suggest a recognition of its importance, balanced with an understanding of ongoing research and development, which supports the rated levels of interest and moderate engagement.
Most discussions acknowledge the promising results of the multi-cancer detection test and express support for its potential clinical utility.
The topics generate high interest due to the innovative nature of liquid biopsies and their implications for early cancer detection.
Comments often highlight enthusiasm for the research, referencing specific studies and potential benefits, showing moderate depth of engagement.
Participants believe this research could significantly influence future cancer diagnostics and patient outcomes, although some express cautious optimism.
Abstract in brief
- The study validated a blood-based test that uses methylation patterns and machine learning to detect multiple types of cancer in people showing symptoms, with high specificity (94-99%) and moderate sensitivity (around 64-84%), especially for gastrointestinal cancers.
- The test was also good at predicting the cancer’s origin, with over 90% accuracy, and it performed similarly in older adults (65+) compared to the overall group.
- Participants with cancers that the test missed had better survival rates than expected, suggesting that the test is more likely to detect more aggressive cancers, providing useful prognostic information for doctors.]
Top posts
Most liked on X and BlueskyMulti-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @JCOPO_ASCO focusing on clinically presenting cancers from the CCGA study. https://t.co/gvQB1WXu0y
New results published in @JCO_ASCO today show the potential of GRAIL’s multi-cancer early detection test to aid in the diagnosis of #cancer in symptomatic patients. Read more: https://t.co/rTBU62bw4A #MCED https://t.co/YL65mgYLUv
RT @BenWestphalen: #cancer
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
All mentions
Evaluating Multi-Cancer Detection Test Performance in Symptomatic Patients
Dr. Eric Klein discusses the validation of a blood-based multi-cancer detection test that uses methylation patterns and machine learning to identify various cancers in symptomatic individuals, highlighting its high…
RT @BenWestphalen: #cancer
RT @BenWestphalen: #cancer
RT @BenWestphalen: #cancer
RT @BenWestphalen: #cancer
RT @BenWestphalen: #cancer
RT @BenWestphalen: #cancer
RT @BenWestphalen: #cancer
RT @BenWestphalen: #cancer
#cancer
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers https://t.co/Qtn0sBuf0L https://t.co/5OQTXKKX5l
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
RT @aadel_chaudhuri: Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @J…
Multi-cancer early detection via liquid biopsy is an exciting frontier. Nice study from @MayoClinic & @GrailBio in @JCOPO_ASCO focusing on clinically presenting cancers from the CCGA study. https://t.co/gvQB1WXu0y
New results published in @JCO_ASCO today show the potential of GRAIL’s multi-cancer early detection test to aid in the diagnosis of #cancer in symptomatic patients. Read more: https://t.co/rTBU62bw4A #MCED https://t.co/YL65mgYLUv